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25 Years of the Onchocerca ochengi Model 
Trends box. 
 The Onchocerca ochengi system has consistently shown that strong, albeit incomplete, natural 
immunity exists in cattle and that partial protection can be induced by both irradiated and 
recombinant vaccines.  
 In accordance with human data, the O. ochengi system has demonstrated that Wolbachia induce 
a profound local neutrophilia within nodules. Recent proteomic data obtained from nodule fluid 
show that adult worms are ‘bathed’ in liberated neutrophil granule contents, especially 
antimicrobial proteins. 
 The Wolbachia endosymbiont of O. ochengi has a highly reduced genome that can produce very 
few vitamins and cofactors, although it may generate energy in the form of ATP for its host. The 
most abundant Wolbachia proteins induce neutrophil activation and chemokinesis. 
 Small RNAs with diagnostic potential are released by Onchocerca spp. into nodule fluid and 
human (and bovine) blood. 
Trends Box
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Abstract:  
Although of limited veterinary significance, Onchocerca ochengi has become famous as a 
natural model or ‘analogue’ of human onchocerciasis (river blindness), which is caused by 
Onchocerca volvulus. On the basis of both morphological and molecular criteria, O. ochengi 
is the closest extant relative of O. volvulus and shares a number of key natural history traits 
with the human pathogen. These include exploitation of the same group of insect vectors 
(blackflies of the Simulium damnosum complex) and formation of collagenous nodules with 
a very similar histological structure to human nodules. Here, we review the contribution of 
this natural system to drug and vaccine discovery efforts, as well as to our basic biological 
understanding of Onchocerca spp., over the past quarter-century. 
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History and basic biology 
In 1992, Parasitology Today published an article by Alexander (Sandy) Trees entitled 
“Onchocerca ochengi: Mimic, Model or Modulator of O. volvulus?” that introduced a 
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relatively obscure filarial species to a wider audience [1]. In our view, the intervening two-
and-a-half decades have clearly demonstrated that O. ochengi has lived up to its initial 
promise and fulfilled its potential as a superlative natural system for the study of 
onchocerciasis. 
 
Onchocerca ochengi was first described by Bwangamoi [2] from bovine skins collected from 
an abattoir in Uganda. The nodules were reported to damage hides at several locations 
across East Africa and reduce their market value (the sole veterinary impact of this disease) 
[3]. Interestingly, this effect on the leather reflected one of the few significant biological 
differences between O. ochengi and Onchocerca volvulus: adults of the former are located 
in intradermal nodules, whereas human O. volvulus nodules are usually subcutaneous. 
Several years later, Bussieras et al. [4] described a similar Onchocerca spp. from cattle in 
Togo that had shorter microfilariae (see Glossary), which was named Onchocerca dermata. 
Subsequent investigations by Bain et al. [5] determined that Bwangamoi had published 
incorrect measurements for O. ochengi microfilariae, and thus O. dermata was abandoned 
as a junior synonym of O. ochengi. 
 
For over a decade, O. ochengi was neglected for onchocerciasis research in favour of other 
bovine Onchocerca species from temperate regions, such as Onchocerca gibsoni and 
Onchocerca lienalis. However, as entomological monitoring to assess the efficacy of 
onchocerciasis control came to the fore in the late 1980s, the potential for larvae of bovine 
Onchocerca spp. in blackflies to complicate the calculation of transmission potentials was 
recognised. This drew increasing attention to O. ochengi, as it is challenging to discriminate 
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between the L3 of this species and that of O. volvulus without recourse to molecular assays 
[6-8]. 
 
In the early 1990s, the remarkable parallels between the natural history of O. ochengi and 
O. volvulus began to attract more international interest, and through collaborations 
between the Liverpool School of Tropical Medicine, Eberhard Karls University (Tübingen) 
and veterinary researchers from Cameroon, O. ochengi eventually supplanted the other 
bovine Onchocerca spp. as the model of choice for chemotherapeutic and immunological 
investigations. Almost everything we know about O. ochengi in cattle has been derived from 
data collected at a single field site adjacent to the River Vina du Sud, a blackfly breeding site 
located near the town of Ngaoundéré in the Adamawa Region of Cameroon (Figure 1). The 
first experiment in naturally-infected cattle examined the relationship between nodule load 
and microfilarial density in animals of different ages, exploiting the accessibility of the 
nodules, which are easily numerated by palpation and can be removed surgically under local 
anaesthesia. This study suggested that immunity to microfilariae, but not adult worms, may 
develop in older animals [9]. Other aspects of the natural history of O. ochengi in its natural 
host were rapidly established, such as the pre-patent period for microfilarial appearance in 
the skin (a minimum of 10 months) and their predilection site (the posterior ventral region) 
in comparison with other bovine Onchocerca spp. found in Cameroon [10,11]. Subsequently, 
longer-term experiments were conducted that revealed fascinating patterns of differential 
susceptibility to infection among cattle, with bulls exhibiting significantly higher nodule and 
microfilarial loads than did cows, and some animals maintaining very low levels of 
parasitosis despite intensive exposure [12]. Importantly, these disparities in susceptibility 
could not be accounted for by differences in attractiveness to the blackfly vector, indicating 
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that natural immunity to O. ochengi can develop under conditions of hyperendemicity 
[12,13]. This has important implications for vaccine development for human onchocerciasis 
(see below). 
 
In parallel with its exploitation for the screening of drugs and vaccine candidates, the 
natural history of O. ochengi continues to be explored in depth. Insights into the 
reproductive biology of the parasite have been provided by genotyping of individual adult 
worms and intrauterine microfilariae collected from different nodules. This demonstrated 
that >50% of gravid worms contained progeny which were sired by more than one male, 
and some nodules contained females that had mated with males that were no longer 
present in the nodule [14]. Intriguingly, the genotyping of individual developing larvae from 
Simulium damnosum sensu lato and additional adult worms from nodules revealed that 16 – 
17% of the “O. ochengi” specimens actually belonged to the taxon Onchocerca sp. “Siisa” 
[15]. This enigmatic member of the genus was previously only known from two developing 
larvae obtained from S. damnosum s. l. in Uganda [16]. Subsequent genotyping studies of 
adult worms, dermal microfilariae and embryonic stages obtained from a single infected 
cow from Ngaoundéré showed that O. ochengi sensu stricto and Onchocerca sp. “Siisa” 
freely interbreed, producing progeny that are viable (although whether hybrids are fertile is 
yet to be confirmed) [17]. Thus, these taxa can be considered strains of the same species 
that may have recently reencountered each other after a period of geographic separation. 
Surprisingly, this same study also reported preliminary evidence for hybridisation between 
O. ochengi and Onchocerca dukei, a species that normally forms nodules on the deep fasciae  
[11,17]. 
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Here, we review the unique contribution of the O. ochengi system to onchocerciasis 
research over the past quarter-century, highlighting important insights it has provided in the 
realms of drug and vaccine evaluation, in addition to the role it has played in deepening our 
understanding of the basic biology of Onchocerca spp. 
 
Contribution to vaccine development 
In one of the first field studies of O. ochengi in Cameroon, comparisons of the prevalence of 
human onchocerciasis around a settlement with a high density of cattle, versus a similar 
area with few cattle, strongly suggested that O. ochengi L3 can induce zooprophylaxis 
against O. volvulus infection by naturally immunising the human host [18]. Subsequently, 
cross-protection was evaluated in the opposite direction by immunising cattle with O. 
volvulus L3, followed by a challenge with O. ochengi L3, which demonstrated almost 100% 
protection [19]. In a series of logistically challenging experiments, cryopreserved O. ochengi 
microfilariae were transported to the UK and injected into a surrogate blackfly vector 
(Simulium ornatum) in order to generate L3 for experimental infections of British cattle 
under controlled conditions. Antibodies from these animals were shown to recognise 
recombinant O. volvulus vaccine candidates, supporting the use of the O. ochengi system for 
onchocerciasis vaccine research [20]. In parallel, studies in Cameroon involving long-term 
follow-up of putatively immune animals under intense field exposure revealed that they 
remained relatively refractory to infection compared with naïve or drug-cured cattle [13]. 
Furthermore, under both experimental and natural conditions, irradiated L3 were 
demonstrated to confer significant reductions in nodule (experimental challenge) or 
microfilarial (natural challenge) loads [13]. 
 
6 
 
Once these foundational experiments were completed, a bovine field trial of recombinant 
antigens that had induced significant levels of protection against filarial nematodes in 
rodent models was undertaken [21]. Eight prioritised vaccine candidates were selected and 
each immunised calf received all eight O. ochengi antigens, which were administered at 
different anatomical sites in the optimal adjuvant for each individual antigen (Freund’s or 
alum). The calves were protected from exposure to blackflies until the immunisation 
schedule was completed, then they were maintained next to the River Vina du Sud for 22 
months. Although 92% of the vaccinated animals developed nodules and had similar nodule 
loads to the controls (which received adjuvant only), 42% of the vaccinated animals did not 
develop microfilaridermia, whereas all control animals were microfilaria-positive. A 
limitation of the study design was that for logistical reasons, the antigens could not be 
evaluated separately in cattle. However, there was a strong trend for the microfilaria-
negative animals to have higher IgG2 antibody levels to a particular antigen representing a 
moiety from tropomyosin [21]. 
 
Role as a macrofilaricidal drug screen 
In 1991, the extremely close relationship between O. ochengi and O. volvulus and the 
accessibility of bovine nodules for assays on adult worms led the World Health Organisation 
to select O. ochengi as a tertiary drug screen (i.e., a system to evaluate compounds 
following earlier rounds of prioritisation using in vitro assays and small animal models). This 
project, named MACROFIL, was supported by the Special Programme for Research and 
Training in Tropical Diseases (TDR) throughout the 1990s and was focused on the search for 
a nontoxic macrofilaricidal drug, which has been the “Holy Grail” of filariasis research for 
decades (and continues to this day). Early experiments demonstrated that the susceptibility 
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of O. ochengi to anthelminthics is similar to that of O. volvulus. Indeed, ivermectin at 200 
g/kg exhibited excellent activity against microfilariae but no significant macrofilaricidal 
effects [22]; whereas a flubendazole derivative (UMF-078) was highly macrofilaricidal [23] 
(although it induced neurological toxicity in cattle if repeated doses were administered 
orally [24]). One of the key strengths of the O. ochengi system is the ability to perform a 
triple assay on excised nodules, comprising measurement of adult worm motility, cellular 
metabolism (assessed by reduction of a tetrazolium salt to a formazan dye), and 
quantification of embryonic stages in female worms [22]. In contrast, for logistical and 
ethical reasons regarding the number of nodules that can be surgically removed from a 
human patient, the triple assay is rarely performed on O. volvulus today. Pharmacokinetic 
analyses of drug concentrations within nodules may also be performed [25]. This combined 
readout is easier to interpret than assessment of worm damage in fixed histological 
sections; albeit the latter method has performed well for human trials of macrofilaricidal 
drugs following expert training in the pathology of O. volvulus nodules [26,27]. Through the 
application of tattoo ink and/or subcutaneous implantation of microchip transponders in 
experimental animals, it is also straightforward to ensure that only nodules that were 
present from the onset of treatment are evaluated in the triple assay [24]. 
 
An ongoing controversy in the onchocerciasis field has been the question of whether 
macrocyclic lactones have any significant macrofilaricidal activity. In the O. ochengi system, 
even monthly doses of ivermectin or doramectin at 500 g/kg (>3 times higher than the 
annual dose used for preventive chemotherapy of human onchocerciasis) were not found to 
have any overt macrofilaricidal effects, although they induced prolonged sterilisation of 
female worms [28]. This result was reminiscent of a clinical trial in humans where a single 
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dose of ivermectin of up to 1.6 mg/kg failed to kill adult O. volvulus [29]. Moreover, 
moxidectin at 200 g/kg (a single dose, or seven consecutive monthly doses) was similarly 
inefficacious against adult O. ochengi [30]. Accordingly, although assessment of moxidectin 
in human clinical trials is ongoing, initial data suggest that it does not kill adult O. volvulus, at 
least after a single dose [31]. 
 
More recently, natural products used in traditional African medicine and veterinary 
medicine have been evaluated against adult O. ochengi, using worms obtained from abattoir 
material maintained in short-term in vitro culture systems [32,33]. This approach has also 
been applied for the screening of existing FDA-approved drugs to identify macrofilaricidal 
activity. Consequently, auranofin (a gold-containing compound used in the treatment of 
rheumatoid arthritis) has been prioritised as a drug that has the potential to be repurposed 
for onchocerciasis control [34]. 
 
Contribution to the discovery of antibiotic efficacy against adult filariae 
During the MACROFIL programme, an animal heavily infected with O. ochengi developed a co-
infection with the dermal bacterium Dermatophilus congolensis and was treated 
intermittently over several months with a long-acting formulation of oxytetracycline. It was 
noted that following antibiotic chemotherapy, all O. ochengi nodules resolved. Since O. 
ochengi has an estimated lifespan of 5 – 10 years, this outcome was entirely unexpected, 
although reports of intracellular bacteria in O. volvulus published 20 years prior suggested a 
potential mechanism of action [35]. A controlled trial of oxytetracycline against O. ochengi 
was initiated using an intermittent regimen administered over a six-month period. 
Remarkably, this regimen led to killing of all adult worms, resolution of nodules, and 
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clearance of microfilariae from the skin nine months after the treatment commenced [30]. 
Electron microscopic observations revealed that intracellular bacteria within adult worm 
tissues (Figure 2), identified by DNA sequencing as Wolbachia endosymbionts, became 
degenerated in treated worms several months before the parasites were killed. In parallel, 
other researchers working with other filarial nematodes in rodent models demonstrated 
that shorter tetracycline regimens led to prophylactic effects, growth retardation and 
blockage of embryogenesis [36-38]. Clinical trials of doxycycline against O. volvulus in 
human clinical trials rapidly followed and reported that daily therapy for six weeks was 
profoundly embryostatic [39]. 
 
Since these seminal discoveries, a major objective of macrofilaricidal drug research has been 
to shorten the antibiotic regimen required for permanent sterilisation or killing of adult O. 
volvulus, as treatments requiring compliance over periods of several weeks have been 
considered too protracted for mass drug administration programmes. In the O. ochengi 
system, intermittent regimens have been consistently shown to be more efficacious than 
continuous treatment for potent macrofilaricidal effects. Thus, a total dose of 140 mg/kg 
administered daily for 14 days is completely ineffective, whereas the same dose delivered 
monthly for six months kills the majority of adult worms within one year [40-42]. 
Importantly, although the 14-day regimen induced a transient depletion of Wolbachia from 
adult worm tissues, endosymbiont populations recrudesced to pre-treatment levels within 
six months [40]. However, considering the logistics of drug distribution and ensuring 
compliance, protracted intermittent regimens are not ideal for human use. In cattle, long-
acting oxytetracycline administered by intramuscular injection provides therapeutic 
coverage for several days, such that a twice-weekly regimen is effectively a continuous 
10 
 
treatment. Condensing the total dose of 140 mg/kg into three weeks rather than six months 
revealed an efficacy against adult female worms of approximately 50% (as measured at one 
year post-treatment) [41]. The shortest regimen of doxycycline used in a human trial that 
showed significant macrofilaricidal effects was four weeks (at 200 mg/day) [43], and recent 
modelling data indicate that the briefest theoretically effective regimen is between two and 
four weeks [44]. These observations highlight the strong similarities in the response of O. 
ochengi and O. volvulus to antibiotics in vivo. 
 
A possible alternative antibiotic for the chemotherapy of filarial infections is rifampicin, 
which has some advantages over doxycycline, including the potential for use in young 
children (doxycycline is contraindicated in children <8 years) and a bactericidal mode of 
action. Rifampicin did not exhibit clear superiority to doxycycline in human trials [45,46], 
although there has been intense interest in combining doxycycline with rifampicin on the 
basis of significantly enhanced efficacy compared with doxycycline alone in a small animal 
model [47]. However, in the O. ochengi system, rifampicin alone or rifampicin plus 
oxytetracycline administered for three weeks showed no benefit over oxytetracycline 
monotherapy [41]. Indeed, there was a trend for rifampicin to reduce both the 
macrofilaricidal and embryostatic effects of oxytetracycline when administered in 
combination, perhaps because of pharmacokinetic interference between these drugs, which 
has been reported for doxycycline and rifampicin combinations in humans [48]. 
Disappointingly, more than 16 years after the first clinical trials of an antibiotic for 
treatment of onchocerciasis, this approach is yet to be implemented on a wide scale; 
although through the efforts of the Anti-Wolbachia Consortium (AWOL), several other 
repurposed antibiotic combinations are currently in clinical trials [49]. Future studies in O. 
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ochengi-infected cattle could further our understanding of the mechanisms of antibiotic 
tolerance in Wolbachia, which to date have only been investigated in vitro [50]. 
 
 
 
What is the role of Wolbachia in O. ochengi? 
 
In the early years after the discovery of Wolbachia in filarial nematodes, our understanding 
of the symbiosis was shaped largely by the sequencing of the genome of Brugia malayi (a 
cause of lymphatic filariasis in humans) and that of its Wolbachia symbiont, wBm [51,52]. In 
particular, the absence of the haem and riboflavin metabolic pathways in the nematode 
genome and their completeness in the symbiont genome suggested that the basis of the 
obligate dependency was nutrient provisioning, which remains the leading hypothesis 
today. However, several lines of data challenge this interpretation, such as the universal 
absence of the haem pathway in the Nematoda [53] (most described members of which do 
not harbour obligate symbionts) and the widespread retention of haem autotrophy in 
bacteria. Moreover, the genome of a naturally aposymbiotic filarial parasite of humans, Loa 
loa, did not reveal any obvious differences in metabolic capacity compared with B. malayi 
[54]. While there are experimental data indicating that exogenous riboflavin can partially 
rescue the deleterious effects of antibiotic treatment of B. malayi in vitro [55], it is likely 
that Wolbachia has different roles in filarial nematodes instead of, or in addition to, nutrient 
provisioning. 
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Several years before the Wolbachia and filarial nematode genomes were available, it was 
already known that antibiotic treatment led to a profound reduction in neutrophil 
infiltration in O. volvulus nodules, and that only Onchocerca extracts containing Wolbachia 
exhibited chemotactic activity for neutrophils in vitro [56]. Subsequent studies in O. 
ochengi-infected cattle involving serial nodulectomies after short-term (ineffective) or 
prolonged (macrofilaricidal) oxytetracycline treatments revealed that intranodular 
neutrophil dynamics mirrored Wolbachia density in adult worms [57]. Thus, short-term 
treatment caused a transient reduction in neutrophil numbers in the nodule, but 
recrudescence of Wolbachia led to restoration of the neutrophil population and worm 
survival. Strikingly, decreases in intranodular neutrophils were accompanied by a 
corresponding increase in local eosinophilia, involving degranulation on the adult worm 
cuticle (Figure 3). This was ephemeral after the short, continuous regimen but continued for 
several months during and after prolonged chemotherapy, such that degranulating 
eosinophils substantially outnumbered neutrophils in regions adjacent to the adult worms 
[57]. 
 
While these data were suggestive that degranulating eosinophils contributed to killing of 
adult worms and that the attraction of neutrophils to Wolbachia may be protecting the 
worms, it was also possible that eosinophils only degranulate on worms after they are 
already dead (or terminally moribund). To test this scenario, O. ochengi-infected cattle were 
treated with an organoarsenical macrofilaricide, melarsomine, or the prolonged 
oxytetracycline regimen [58]. Importantly, initial in vitro studies demonstrated that 
melarsomine had no effect on the viability of Wolbachia. Statistically significant increases in 
intranodular eosinophil populations were only observed in antibiotic-treated animals, and a 
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significant elevation in degranulating eosinophils was also restricted to this group. Further 
histological analyses revealed that eosinophil degranulation was initiated on worms that 
were morphologically normal, with unchanged gene expression for a marker of viability. 
Finally, ultrastructural studies showed that in antibiotic-treated but not melarsomine–
treated cattle, eosinophil degranulation caused frank damage to the worm cuticle and these 
cells were even observed free in the parasite pseudocoelom. Taken together, these data 
strongly supported the hypothesis that Wolbachia has a defensive mutualist role in O. 
ochengi, protecting adult worms from eosinophil degranulation by stimulating an ineffective 
neutrophil response [58]. 
 
While the precise mechanisms by which the attraction of neutrophils by Wolbachia prevent 
eosinophil degranulation on adult worms are unclear, it is known that Wolbachia products 
can be exposed to the immune system by several routes (in addition to worm death), such 
as release of bacteria from the reproductive tract [59,60] and secretory pore [61], and even 
localisation of Wolbachia surface protein (WSP) in the nematode cuticle [62,63] (Figure 4, 
Key Figure). Plausible molecular interactions with eosinophils in the periphery of the nodule 
that could prevent degranulation on worms under normal circumstances include lactoferrin 
from neutrophils (present in high concentrations in O. ochengi nodule fluid [64]) and/or 
release of lipopeptides (from Wolbachia), which have been shown to inhibit eosinophil 
migration in humans and mice, respectively [65,66]. 
 
Almost certainly, “one size does not fit all” when it comes to the symbiosis between 
Wolbachia and filarial nematodes. Highly motile or migratory filarial species, including the 
lymphatic filariae and non-nodule-forming Onchocerca spp. (such as Onchocerca gutturosa) 
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are very unlikely to depend on this particular immune evasion mechanism as they are not a 
‘sitting target’ for eosinophils. Intriguingly, Onchocerca flexuosa, which is the only known 
aposymbiotic member of the genus, fails to attract neutrophils and resides in nodules with a 
high density of eosinophils [56,67]. Unlike O. ochengi, O. flexuosa has an estimated lifespan 
of only one year [68], which is approximately the same length of time it takes for O. ochengi 
to be killed by eosinophils following antibiotic chemotherapy. 
 
O. ochengi in the genomic era 
Although some high-throughput studies of O. ochengi were attempted using mass 
spectrometric methods prior to release of an O. ochengi genome (for instance, to identify 
diagnostic biomarkers [69]), these analyses were constrained by the phylogenetic distance 
between this species and its nearest sequenced relatives. However, in the past five years, 
there has been an explosion of Onchocerca genome data made freely available (see 
WormBase ParaSite http://parasite.wormbase.org), including a very high-quality reference 
genome for O. volvulus [from the Wellcome Trust Sanger Institute (WTSI) using material 
from Cameroon], a draft genome for O. flexuosa (WTSI sequencing of material from Spain), 
and two draft genomes for O. ochengi (sequencing by University of Edinburgh and WTSI 
using material from Cameroon). 
 
The advent of next-generation sequencing also enabled further insights into Wolbachia 
genomics, with the complete symbiont genome from O. ochengi representing the first from 
its phylogenetic clade (strain wOo from supergroup C). The wOo genome is the smallest 
Wolbachia genome sequenced to date (11% smaller than the supergroup D genome, strain 
wBm, from B. malayi) and lacks the riboflavin metabolic pathway, although the capacity for 
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haem biosynthesis is retained [70]. Recent comparative genomics of supergroup C, including 
a new Wolbachia genome from the dog heartworm, Dirofilaria immitis, have revealed that 
clade C exhibits unique features, such as pronounced GC skew, a lack of transposable 
elements, and significant long-range synteny [71]. Expression studies (transcriptomics and 
proteomics) of strain wOo showed that it does not resemble what would be expected for a 
classical nutritional symbiont, in that genes for vitamin and cofactor synthesis were poorly 
expressed [70]. The only highly expressed proteins with a potential role in metabolic 
provisioning were enzymes involved in the synthesis of purine nucleoside triphosphates, 
suggesting that Wolbachia may act as a ‘supplementary mitochondrion’ and provide ATP for 
the energy requirements of its host. Subsequent studies on B. malayi also supported such a 
role for Wolbachia [72,73]. Perhaps more importantly, several of the most highly expressed 
proteins in wOo [64,70] are known or suspected to activate neutrophils, especially WSP [74] 
and peptidoglycan-associated lipoprotein [75,76].  
 
The availability of the O. ochengi genome (and the O. volvulus genome as a comparator) has 
recently enabled the first high-throughput analysis of an Onchocerca spp. across the major 
stages of the lifecycle [64] using a proteomics approach. In addition, it has also facilitated 
unprecedented insights into the composition of the tiny volume of interstitial fluid that 
surrounds adult worms in the nodule. As might be expected for a nematode with such a 
long lifespan, the major parasite-derived products in nodule fluid are antioxidant enzymes 
(such as peroxiredoxins) and immunomodulatory proteins (including transforming growth 
factor- homologues and a member of a novel family of ShK-domain proteins). In 
accordance with the classical histological studies of Onchocerca nodules described above, 
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the most abundant host-derived proteins in nodule fluid are antimicrobial effectors released 
by neutrophils [64]. 
 
One of the major priorities for human onchocerciasis research is to greatly improve 
diagnostics by becoming less dependent on insensitive skin snipping methods to detect 
microfilariae. Indeed, the ability to detect secreted or excreted products from a single viable 
adult female worm by a non-invasive method could revolutionise the surveillance of 
onchocerciasis and post-control evaluation. The cattle system has made an important 
contribution to this goal by the identification of Onchocerca-derived small RNAs released 
into nodule fluid and bovine serum in vivo [77,78], and the stage-specific proteomic 
analyses also have a key role to play in this regard. Thus, in O. ochengi, quantitative analysis 
of protein expression (Figure 5) has demonstrated that very few proteins are uniquely 
expressed by adult female worms (at least in robustly detectable quantities). However, one 
such female-specific protein (containing a bactericidal permeability-increasing superfamily 
domain) had not been reported previously from filarial worms [64] and could represent a 
target for new diagnostics. 
 
Concluding remarks 
In 1981, Odile Bain [79] hypothesised that O. volvulus speciated from O. ochengi following a 
host-switching event during the domestication of cattle. If this hypothesis is correct (see 
Outstanding Questions), the evolutionary distance between these species is miniscule in the 
wider context of nematode evolution, since domesticated cattle only entered sub-Saharan 
Africa 5 000 years ago [80]. The availability of the O. volvulus and O. ochengi genomes now 
allow this hypothesis to be formally tested, but whatever the outcome of this analysis, the 
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past 25 years have consistently shown that these sister species are extremely close in 
almost every major aspect of their biology. Therefore, as the drive to evaluate 
macrofilaricidal drugs, vaccines and novel diagnostics increases in urgency, O. ochengi is set 
to continue to provide a unique preclinical system for onchocerciasis research. 
 
Glossary 
Aposymbiotic: Lacking symbiotic relationships in the natural state. 
Embryostatic: An outcome of drug or vaccine action defined by the cessation of embryonic 
development in the female reproductive tract. 
L3: The third-stage infective larva. 
Macrofilaricidal: Capable of killing adult filarial worms. 
Microfilariae: The highly motile, transmissible first-stage larvae of filarial nematodes, which are born 
live and accumulate in either the skin or the blood depending on the species. 
Microfilaridermia: The presence of microfilariae in the skin. 
Synteny: Conservation of blocks of gene order between different chromosomes. 
Zooprophylaxis: Reduced disease transmission to humans due to the diluting effect of animal 
populations. 
 
Acknowledgments 
We acknowledge the pioneering work of Sandy Trees and Alfons Renz that established the 
O. ochengi model in the early 1990s; the vision of Ted Bianco and David Taylor who brought 
it to the fore for vaccine research; and long-term funding support for this system from the 
European Commission.
18 
 
Figure legends 
Figure 1. Key Field Site for Onchocerca ochengi Research under Natural Conditions. A. 
Location of the field site (purple star) on the Adamawa Plateau of northern Cameroon. B. 
The River Vina du Sud near Ngaoundéré where the main vector for Onchocerca ochengi in 
the region, Simulium squamosum [13,81], breeds in high densities. 
 
Figure 2. Localisation of Wolbachia Endosymbionts in Onchocerca ochengi. A. A cross-
section of an adult female O. ochengi surrounded by neutrophils (n; Giemsa stain) inside a 
bovine intradermal nodule. Wolbachia endosymbionts (stained with an anti-Wolbachia 
surface protein antibody, brown deposits) are located in the somatic hypodermal cords 
(yellow arrow) and within developing microfilariae (yellow arrowhead) inside the uteri(u). 
The location of the worm intestine is also indicated (i). Scale bar, 50 m. Reproduced from 
[58] under a CC-BY license. B. Numerous Wolbachia cells (arrows) are shown at higher 
magnification within host-derived vacuoles (v) in a somatic hypodermal cord beneath the 
cuticle (c). The locations of glycogen deposits (g) and mitochondria (m) are also shown. Scale 
bar, 1 m.  
 
Figure 3. Breakdown of Mutualism after Antibiotic Chemotherapy Triggers Eosinophil 
Degranulation. Numerous bovine eosinophils release toxic granules (Giemsa stain; black 
arrows) onto the surface of an adult female Onchocerca ochengi (asterisk) eight weeks after 
commencement of oxytetracycline treatment. Note the absence of neutrophils (cf. Figure 
2A). The locations of the worm epicuticle (ec) and a vacuolated hypodermal cord cell (vhc) 
are indicated. Scale bar, 10 m.  
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Figure 4 (Key Figure). Routes by which Wolbachia Products Interact with the Host Immune 
System. Wolbachia can be liberated from viable adult female filariae by a number of routes, 
including expulsion of free bacteria from the vulva along with microfilariae during 
parturition (1) [60], escape via the secretory pore (2) [61], and secretion of Wolbachia 
surface proteins into the cuticle (3) [62,63]. In addition, natural or drug-induced death of all 
parasite stages within the definitive host will result in substantial releases of endosymbionts 
[82-84] (not shown). Intact bacteria and secreted or excreted Wolbachia products attract 
neutrophils (5), forming a barrier around adult Onchocerca ochengi in the nodule [56,57]. 
Following prolonged antibiotic chemotherapy, Wolbachia is depleted, leading to a sharp 
decline in local neutrophilia and a corresponding influx of eosinophils (6), which degranulate 
on the worm cuticle [57,58]. It is not known how Wolbachia might prevent intranodular 
eosinophilia, but high concentrations of neutrophil-derived lactoferrin (7), or lipoproteins 
released by Wolbachia (8), are plausible mechanisms [65,66]. 
 
Figure 5. Heat Map of Protein Abundance across the Onchocerca ochengi Lifecycle. 
Proteins were quantified by label-free mass spectrometry and dendrograms were generated 
by hierarchical clustering based on pair-wise distance. Stage-specific clusters of expression 
and selected proteins of interest are highlighted for intrauterine microfilariae (iuMf, purple), 
vector-derived infective larvae (vL3, red), nodule fluid (NF, black), adult males (AM, blue) 
and adult females (AF, pink). UNC, uncoordinated; G protein, guanine nucleotide-binding 
protein; ASP, activation-associated secreted proteins; ACAD, acyl-CoA dehydrogenase; TGF, 
transforming growth factor; MSP, major sperm protein; PSP, protein serine-threonine 
phosphatase; CBS, cystathionine beta-synthase; BPI, bactericidal permeability-increasing. 
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Numbers in parentheses represent the number of proteins quantified in each family. Figure 
reproduced from [64] under a CC-BY licence.
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25 Years of the Onchocerca ochengi model. 
Outstanding Questions box 
 What is the precise status of Onchocerca sp. “Siisa” in terms of its taxonomic relationship with O. 
ochengi and O. volvulus? Does it represent an East African strain of O. ochengi that has only 
recently arrived in West Africa? Are hybrids of “Siisa” and O. ochengi sensu stricto equally fertile 
as the offspring arising from within-strain matings? Similar questions pertain to the putative 
hybridization reported between O. ochengi and O. dukei in Cameroon. 
 Why do all antibiotics evaluated to date require several weeks to irreversibly deplete Wolbachia 
from O. ochengi and other filarial worms? What are the molecular mechanisms underlying 
antibiotic tolerance and the ability of Wolbachia to recrudesce after relatively short drug 
regimens? 
 How does the neutrophil recruitment stimulated by Wolbachia prevent eosinophil influx and 
degranulation in the nodule? What are the relative roles of physical exclusion, 
immunomodulation of granulocyte function and cell death? Could an immunotherapeutic 
approach boost the efficacy of short-term antibiotic treatments? 
 What is the evolutionary history of O. ochengi and O. volvulus and did they really diverge as little 
as 5 000 years ago? What is the molecular basis of host specificity? On a continent-wide scale, 
how does the diversity of the two species compare and can the origin of the putative host switch 
be pinpointed? 
 Will it be possible to accelerate vaccine development for human onchocerciasis by finding a 
practicable combination of antigens and adjuvants that induces substantive and long-lasting 
protection in the O. ochengi system? What are the mechanisms underlying prevention of 
microfilaridermia in the original recombinant vaccine trial in cattle? 
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